Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host DiseaseBusiness Wire • 03/25/22
Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual MeetingBusiness Wire • 03/18/22
Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of VitiligoBusiness Wire • 03/14/22
Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic CancerGlobeNewsWire • 03/01/22
Incyte's (INCY) CEO Hervé Hoppenot on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/08/22
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical ProgramsBusiness Wire • 02/08/22
12 biotech stocks to consider buying now as prospects for the sector brighten this yearMarket Watch • 02/06/22
Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitisPRNewsWire • 01/28/22
Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With MerusBenzinga • 01/26/22